<?xml version="1.0" encoding="UTF-8"?>
<ref id="B336-viruses-12-00110">
 <label>336.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Capci Karagoz</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Reiter</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Seo</surname>
    <given-names>E.J.</given-names>
   </name>
   <name>
    <surname>Gruber</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Hahn</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Leidenberger</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Klein</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Hampel</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Friedrich</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Marschall</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin</article-title>
  <source>Bioorg. Med. Chem.</source>
  <year>2018</year>
  <volume>26</volume>
  <fpage>3610</fpage>
  <lpage>3618</lpage>
  <pub-id pub-id-type="doi">10.1016/j.bmc.2018.05.041</pub-id>
  <pub-id pub-id-type="pmid">29887512</pub-id>
 </element-citation>
</ref>
